Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Compared with placebo, ATH434 demonstrated a statistically significant 48% slowing of clinical progression (based on UMSARS score) at the 50mg dose at week 52. The Food and Drug Administration (FDA) ...
MELBOURNE, Australia and SAN FRANCISCO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Study coordinators who want to add a study should Submit a Clinical Trial. For more information or to remove a study, please email pa-webteam@bcm.edu. MyChart is a ...
The cause of MSA remains unknown. Several lines of evidence suggest that inflammation could contribute to neurodegeneration in MSA. [9–11] Microglia are the primary immune effector cells in the brain.
MedPage Today on MSN
Is pure autonomic failure a warning sign for Parkinson's? What a new study shows.
High conversion rates to Parkinson's, dementia with Lewy bodies, or multiple system atroph ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In 2024, Healio covered several stories about trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results